Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel (D) subgroup.

被引：0
|
作者：
Cislo, Paul
Reuning-Scherer, Jonathan D.
机构：
[1] Bayer HealthCare, Whippany, NJ USA
[2] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
254
引用
收藏
页数：1
相关论文
共 50 条
  • [41] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
    Finkelstein, S. E.
    Michalski, J. M.
    O'Sullivan, J.
    Parker, C.
    Garcia-Vargas, J.
    Sartor, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
  • [42] Hematologic safety of Ra-223 dichloride (Ra-223) in castration- resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Fang, F.
    Vogelzang, N. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 60
  • [43] Radium-223 Dichloride For Castration Resistant Metastatic Prostate Cancer - Usefulness Of The Response Evaluation Using Ra-223 Czt Spect/ct For Quantitative Analysis
    Nakayama, M.
    Okizaki, A.
    Uno, T.
    Suzuki, T.
    Mikami, Y.
    Sato, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S567 - S567
  • [44] 1.5-Year Post-Treatment Follow-Up of Radium-223 Dichloride (Ra-223) in Patients With CastrationResistant Prostate Cancer (CRPC) and Bone Metastases From the Phase 3 ALSYMPCA Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (04) : 9 - 10
  • [45] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, G.
    Fang, F.
    Vogelzang, N. J.
    ONKOLOGIE, 2013, 36 : 78 - 78
  • [46] 3-year safety follow-up of Radium-223 Dichloride (Ra-223) in patients (Pts) with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Kramer, M. W.
    Kuczyk, M. A.
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Coleman, R. E.
    Fang, F.
    Skjorestad, I
    Nilsson, S.
    Oncology Research and Treatment, 2015, 38 : 266 - 266
  • [47] Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Parker, C.
    Heinrich, D.
    Bottomley, D.
    Hoskin, P.
    Franzen, L.
    Solberg, A.
    Pawar, V.
    Reuning-Scherer, J.
    O'Bryan-Tear, C. G.
    Nilsson, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S689 - S689
  • [48] 3-year safety yellow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Parker, Chris
    Vogelzang, Nicholas J.
    Salter, A. Oliver
    Coleman, Robert E.
    Fang, Fang
    Skjorestad, Irene
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [49] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
12345